DIVI S LABORATORIES LTD vs NURECA LIMITED
A side-by-side comparison of DIVI S LABORATORIES LTD (DIVISLAB) and NURECA LIMITED (NURECA) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, DIVI S LABORATORIES LTD leads DIVISLAB vs NURECA on 11 of 14 metrics (1 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation22
- Profitability40
- Growth10
- Size & financial health40
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
EvenHow expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
DIVISLAB takes 4/4How efficiently each company turns capital and sales into profit. Higher is better.
Growth
DIVISLAB takes 1/2Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
DIVISLAB takes 4/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 39.0%"]
- − ["Stock is trading at 14.6 times its book value", "The company has delivered a poor sales growth of 8.67% over past five years."]
- + ["Company has reduced debt.", "Company is almost debt free."]
- − ["Though the company is reporting repeated profits, it is not paying out dividend", "The company has delivered a poor sales growth of -7.19% over past five years.", "Company has a low return on equity of -0.56% over last 3 years.", "Earnings include an other income of Rs.7.35 Cr."]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.